Hologic Is Teaming Up with ‘The Real’ to Spread the Word About Breast Cancer Screening!

“The Real” is joining forces with Hologic, Inc. to promote breast cancer screening!

Hologic is the innovative company behind the Genius® 3D Mammography™ exam, the only mammogram FDA approved as superior to conventional mammography for all women, including those with dense breasts.¹ It also detects 20-65% more invasive breast cancers compared to 2D mammography alone.²

The world leader in breast health, Hologic recently launched Project Health Equality, a multi-year initiative aimed at diminishing screening disparities for Black and Hispanic women through research, education, and access.

In partnership with the Black Women's Health Imperative (BWHI), the National Alliance for Hispanic Health, and RAD-AID, the initiative aims to:

• Create awareness campaigns that give women a better understanding of their risks as well as screening and treatment options.
• Research cultural, social, and economic disparities to make sure Black and Brown women in the U.S. can access and receive the best health care possible.
• Invest in care delivery organizations that target underserved women in need of 3D mammograms, cervical cancer screening, and abnormal uterine bleeding solutions.

Additionally, Hologic’s partnership with BWHI includes the P.O.W.E.R. of Sure campaign, featuring the Grammy-winning Mary J. Blige, which encourages Black women to schedule and attend their annual mammograms. While the incidence of breast cancer is about the same for Black and white women, the breast cancer death rate is 40% higher in Black women.³

Overall, when breast cancer is detected early, a woman’s chance of survival is greater.

For more information about the P.O.W.E.R. of Sure campaign, head over to BeSure.BWHI.org.

¹FDA Approvals P080003, P080003/S001, P080003/S004, P080003/S005

²“Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.”